The Effect of Albuterol Repetabs on Pulmonary Function in Individuals with Chronic Spinal Cord Injury.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 41587730.
- Also identified by DOI 10.1016/j.apmr.2026.01.013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To determine the effect of 12 weeks of twice daily albuterol repetabs on pulmonary function in persons with chronic spinal cord injury. 12-week prospective, double-blinded, placebo-controlled trial SETTING: Research laboratories PARTICIPANTS: 32 individuals with chronic spinal cord injury INTERVENTION: Albuterol repetabs or placebo, twice daily, for twelve weeks. Pulmonary function tests and maximum inspiratory and expiratory pressures RESULTS: Interaction effects were found for expiratory reserve volume and forced expiratory volume. Improvements in the drug group were found for total lung capacity, vital capacity, expiratory reserve volume, and maximal inspiratory pressure. Forced expiratory volume in 1 second did not change in the drug group but trended towards a significant decrease in the placebo group. 12-weeks of albuterol treatment improved overall pulmonary function and ventilatory muscle strength, compared to placebo, in those living with spinal cord injury.